Moore Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Moore Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-75,000	Closed	-$491K	–	692
2020 Q4	$491K	Hold	75,000	–	–	0.01%	457
2020 Q3	$499K	Hold	75,000	–	–	0.01%	323
2020 Q2	$625K	Sell	75,000 -25,000	-25%	-$232K	0.02%	220
2020 Q1	$767K	Hold	100,000	–	–	0.03%	137
2019 Q4	$831K	Hold	100,000	–	–	0.03%	209
2019 Q3	$738K	Sell	100,000 -25,000	-20%	-$247K	0.03%	244
2019 Q2	$1.4M	Hold	125,000	–	–	0.03%	240
2019 Q1	$1.34M	Hold	125,000	–	–	0.04%	221
2018 Q4	$1.89M	Hold	125,000	–	–	0.07%	155
2018 Q3	$2.31M	Buy	+125,000	New	+$2.85M	0.05%	187

Other funds holding CTMX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Moore Capital Management's CTMX Position: Q1 2021 in Review

Moore Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 75,000 shares — an estimated $491K sold.

Moore Capital Management first reported a position in CTMX in Q3 2018 and held it in 10 quarters. The position peaked at $2.31M in Q3 2018. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

Moore Capital Management reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
Moore Capital Management sold 75,000 CytomX Therapeutics shares in Q1 2021, an estimated $491K.
Moore Capital Management first reported a position in CytomX Therapeutics in Q3 2018 and held it in 10 quarters.
Moore Capital Management's CytomX Therapeutics position peaked at $2.31M in Q3 2018.
126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Moore Capital Management's 13F filing for Q1 2021, filed 17 May 2021.